Last Commented Health Blogs (952)

In response to:


Researchers Find Coronavirus on Pollution Particles

By Ron Brackett 5 hours ago

At a Glance

Preliminary results find evidence of the novel coronavirus on air pollution over Bergamo, Italy.

Bergamo is one of Italy's most polluted provinces. Scientists agree more study is needed.

Italian researchers say they have found evidence of the novel coronavirus on tiny particles of air pollution.

The work is preliminary, and it appears on a site that preprints studies before they have been peer reviewed.

Air samples were collected at two sites in Bergamo province in northern Italy's Lombardy region, the area of the country hit hardest by the pandemic. Testing found a gene highly specific to COVID-19 in multiple samples from the province, one of the most polluted in Italy.

An independent laboratory confirmed the gene detection by blind testing, The Guardian reported.

Separate research groups have suggested pollution particles may carry the coronavirus particles farther.

The work was led by Leonardo Setti, an industrial chemist at the University of Bologna. He said it's important now to investigate whether the coronavirus can be carried more widely by air pollution.

“I am a scientist and I am worried when I don’t know,” he told The Guardian. “If we know, we can find a solution. But if we don’t know, we can only suffer the consequences.”

Jonathan Reid, a Bristol University professor researching airborne transmission of coronavirus, told The Guardian, “It is perhaps not surprising that while suspended in air, the small droplets could combine with background urban particles and be carried around.”

Earlier studies have found that people exposed to higher levels of air pollution were more likely to die from COVID-19.

In response to:

Coronavirus: In a race against time, vaccine testing expands

In the battle to prevent COVID-19 infection, a vaccine will be our safest armor.

As casualties climb, pharmaceutical companies and young volunteers are racing to design, build and test a defense that can protect us. Unless a vaccine is developed soon, people susceptible to the virus will continue to be at risk.

Human testing has begun of six potential vaccines in an effort to prove that they’re safe and can produce an immune response. Over 70 more are being reviewed for safety and effectiveness in preparation for human testing. In promising news, this week Chinese researchers reported that one candidate has already proven its usefulness in animals, protecting monkeys from infection.

Meanwhile, more than 3,200 young volunteers from 52 nations have enlisted to speed up research, registering with the group 1DaySooner.org to be vaccinated and then deliberately exposed to the virus in the final phase of testing, so scientists can more quickly learn if this armor works.

“If it accelerates vaccine development by a month, that prevents hundreds of thousands of infections, saving lives,” said Carson Poltorack, 23, a Stanford graduate soon to pursue dual MD/PhD degrees at the University of Pennsylvania. Young and healthy, he signed up to volunteer because “I would much rather be the one shot at — I have a far lower chance of dying or having a serious outcome than other groups.”

Despite these efforts, the battle will be neither simple nor fast. Determining a vaccine’s safety and effectiveness takes time, said experts.

The process will take a year to a year and a half, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, in early March. Other experts think it will take even longer.

Until a vaccine is developed, it’s likely that there will be a new wave of infections when stay-at-home orders are eased. People at high risk of developing COVID-19 — including those over 65 or with underlying medical conditions — will again be vulnerable to infection by the potentially deadly disease.

Vaccines are important because the human body responds to infection too slowly to protect itself.

When a person is exposed, their immune system launches a defense. It responds by generating antibodies that specifically recognize proteins from the virus, called SARS-CoV-2. These antibodies trigger white blood cells that eliminate the virus.

But by the time these immune cells are ready, the virus has already taken over host cells. It’s too late.

A person is protected from future infection only after recovery. So-called “memory cells” prompt a faster immune response the next time SARS-CoV-2 invades their body.

Vaccines work by triggering production of these antibodies and memory cells — without forcing a person to suffer through the illness.

One approach, used by the Massachusetts biotech company Moderna, introduces a spike-shaped protein found on the surface of SARS-CoV-2, which could put our immune systems on alert without actually giving us the disease. A second round of tests is being conducted at Kaiser Permanente Washington Health Research Institute in Seattle, suggesting there were no adverse effects so far.

Another approach, used by China-based Sinovac Biotech and others, uses an inactivated form of the virus, which could prime our immune systems without the consequences of COVID-19. Seven days after monkeys vaccinated by Sinovac were exposed to the virus, it could not be detected in their bodies, according to a report published April 19 on the preprint server bioRxiv. But only eight monkeys were tested, and they don’t develop the most severe symptoms the virus causes in humans.